Background.The risk of wound healing complications (WHCs) and the early use of mammalian target of rapamycin inhibitors after kidney transplantation (KT) have not been fully addressed.Methods.The NEVERWOUND study is a 3-month, multicenter, randomized, open-label study designed to evaluate whether a delayed (ie, 28 +/- 4 d posttransplant) immunosuppression regimen based on everolimus (EVR) reduces the risk of WHC versus EVR started immediately after KT. Secondary endpoints were treatment failure (biopsy-proven acute rejection, graft loss, or death), delayed graft function, patient and graft survival rates, and renal function.Results.Overall, 394 KT recipients were randomized to receive immediate (N = 197) or delayed (N = 197) EVR after KT. At 3 months, WHC-free rates in the immediate EVR versus delayed EVR arm, considering the worst- and best-case scenario approach, were 0.68 (95% confidence interval [CI], 0.62-0.75) versus 0.62 (95% CI, 0.55-0.68) (log-rank P = 0.56) and 0.70 (95% CI, 0.64-0.77) versus 0.72 (95% CI, 0.65-0.78) (log-rank P = 0.77), respectively. The 3- and 12-month treatment failure rates, delayed graft function and renal function, and patient and graft survival were not different between the arms.Conclusions.The early introduction of EVR after KT did not increase the risk of WHC, showing good efficacy and safety profile.

Manzia, T.m., Carmellini, M., Todeschini, P., Secchi, A., Sandrini, S., Minetti, E., et al. (2020). A 3-month, multicenter, randomized, open-label study to evaluate the impact on wound healing of the early (vs delayed) introduction of everolimus in De Novo Kidney transplant recipients, with a follow-up evaluation at 12 months after transplant (NEVERWOUND study). TRANSPLANTATION, 104(2), 374-386 [10.1097/TP.0000000000002851].

A 3-month, multicenter, randomized, open-label study to evaluate the impact on wound healing of the early (vs delayed) introduction of everolimus in De Novo Kidney transplant recipients, with a follow-up evaluation at 12 months after transplant (NEVERWOUND study)

Manzia T. M.;Spagnoletti G.;Tisone G.
2020-01-01

Abstract

Background.The risk of wound healing complications (WHCs) and the early use of mammalian target of rapamycin inhibitors after kidney transplantation (KT) have not been fully addressed.Methods.The NEVERWOUND study is a 3-month, multicenter, randomized, open-label study designed to evaluate whether a delayed (ie, 28 +/- 4 d posttransplant) immunosuppression regimen based on everolimus (EVR) reduces the risk of WHC versus EVR started immediately after KT. Secondary endpoints were treatment failure (biopsy-proven acute rejection, graft loss, or death), delayed graft function, patient and graft survival rates, and renal function.Results.Overall, 394 KT recipients were randomized to receive immediate (N = 197) or delayed (N = 197) EVR after KT. At 3 months, WHC-free rates in the immediate EVR versus delayed EVR arm, considering the worst- and best-case scenario approach, were 0.68 (95% confidence interval [CI], 0.62-0.75) versus 0.62 (95% CI, 0.55-0.68) (log-rank P = 0.56) and 0.70 (95% CI, 0.64-0.77) versus 0.72 (95% CI, 0.65-0.78) (log-rank P = 0.77), respectively. The 3- and 12-month treatment failure rates, delayed graft function and renal function, and patient and graft survival were not different between the arms.Conclusions.The early introduction of EVR after KT did not increase the risk of WHC, showing good efficacy and safety profile.
2020
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/18 - CHIRURGIA GENERALE
English
Manzia, T.m., Carmellini, M., Todeschini, P., Secchi, A., Sandrini, S., Minetti, E., et al. (2020). A 3-month, multicenter, randomized, open-label study to evaluate the impact on wound healing of the early (vs delayed) introduction of everolimus in De Novo Kidney transplant recipients, with a follow-up evaluation at 12 months after transplant (NEVERWOUND study). TRANSPLANTATION, 104(2), 374-386 [10.1097/TP.0000000000002851].
Manzia, Tm; Carmellini, M; Todeschini, P; Secchi, A; Sandrini, S; Minetti, E; Furian, L; Spagnoletti, G; Pisani, F; Piredda, Gb; Cappelli, G; Tisone, ...espandi
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
10TRANSPL2020.pdf

non disponibili

Licenza: Non specificato
Dimensione 1.22 MB
Formato Adobe PDF
1.22 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/311996
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 5
social impact